Cannabis and parkinsons
Browse the latest research linking medical marijuana / medicinal cannabis and parkinsons.
Click on a study title below to open a new tab with full article, or click on a compound to see it's full list of research.
Compounds Topics Title Date
Nerolidol anti-inflamatory,parkinsons,neuroprotective in mice Neuroprotective effect of nerolidol against neuroinflammation and oxidative stress induced by rotenone Aug 2016
Our findings are the first to show that the neuroprotective effect of nerolidol is mediated through its anti-oxidant and anti-inflammatory activities, which strongly supports its therapeutic potential for the treatment of PD.
cannabis parkinsons via review Marijuana for Parkinsons Disease? Jan 2019
Neutral  Medical marijuana might benefit motor and nonmotor aspects of Parkinsons disease patients. Currently, these assertions are not substantiated in human investigations and cannabis can also induce side effects. Until studies clarify the safety and efficacy of pharmacotherapy with cannabis products, medical marijuana remains largely without scientific endorsement.
Pinene alzheimers,parkinsons in vitro Inhibition of Acetylcholinesterase Activity by Bicyclic Monoterpenoids Feb 2005
alpha-pinene and (+)-3-carene were potent inhibitors of AChE.
cannabinoids parkinsons in humans via review Evidence for the use of cannabinoids in Parkinson's disease. May 2019
There is increasing understanding of the endocannabinoid system, and the distribution of cannabinoid receptors in basal ganglia structures might suggest potential benefit on parkinsonian symptoms. Concerning clinical research, only one of to date four conducted randomized placebo-controlled trials showed an effect on motor symptoms with alleviation of levodopa-induced dyskinesia. There are a growing number of uncontrolled trials and case reports that suggest beneficial effects of cannabinoids in PD patients.
cannabinoids parkinsons via review The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease Aug 2019
CB1 and CB2 receptors participate in multiple pathogenesis of PD. The agonists or antagonists of CB1 and CB2 receptors are promising in the treatment of PD.